Critical Survey: Commonwealth Bank of Australia (CSLLY) and Its Rivals

Commonwealth Bank of Australia (OTCMKTS: CSLLY) is one of 574 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Commonwealth Bank of Australia to similar companies based on the strength of its profitability, earnings, dividends, risk, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Commonwealth Bank of Australia and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Commonwealth Bank of Australia N/A N/A N/A
Commonwealth Bank of Australia Competitors -1,494.56% -870.08% -29.14%

Risk & Volatility

Commonwealth Bank of Australia has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Commonwealth Bank of Australia’s competitors have a beta of 1.20, meaning that their average share price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

0.3% of Commonwealth Bank of Australia shares are owned by institutional investors. Comparatively, 45.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dividends

Commonwealth Bank of Australia pays an annual dividend of $0.76 per share and has a dividend yield of 1.0%. Commonwealth Bank of Australia pays out 39.8% of its earnings in the form of a dividend. As a group, “Pharmaceutical preparations” companies pay a dividend yield of 2.1% and pay out 32.1% of their earnings in the form of a dividend. Commonwealth Bank of Australia lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Commonwealth Bank of Australia and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Commonwealth Bank of Australia 0 0 0 0 N/A
Commonwealth Bank of Australia Competitors 5105 14243 29356 1077 2.53

As a group, “Pharmaceutical preparations” companies have a potential upside of 62.34%. Given Commonwealth Bank of Australia’s competitors higher possible upside, analysts clearly believe Commonwealth Bank of Australia has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares Commonwealth Bank of Australia and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Commonwealth Bank of Australia $7.92 billion $1.73 billion 41.35
Commonwealth Bank of Australia Competitors $2.14 billion $227.34 million -3.61

Commonwealth Bank of Australia has higher revenue and earnings than its competitors. Commonwealth Bank of Australia is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

About Commonwealth Bank of Australia

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. It also operates approximately 140 plasma collection centers. In addition, this segment conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and developsinfluenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Receive News & Ratings for Commonwealth Bank of Australia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Commonwealth Bank of Australia and related companies with MarketBeat.com's FREE daily email newsletter.